Lupin Pharma
This sponsor has funded 4 studies across 14 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 8044 | Finalised | Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and... | Yes | Yes |
| 9871 | Finalised | Evaluation of the Effectiveness of Risk Minimization Measures: Trimetazidine Drug Utilization Study in European Countries using databases – analysis... | No | Yes |
| 12241 | Finalised | Drug utilisation study (DUS) on flupirtine-containing medicinal products | Yes | Yes |
| 37943 | Ongoing | An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients with... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Lupin Pharma
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Lupin Pharma
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Lupin Pharma
14 Study countries specified are the following:
- Bulgaria
- Czechia
- Estonia
- France
- Germany
- Hungary
- Latvia
- Lithuania
- Poland
- Portugal
- Romania
- Slovakia
- Spain
- United Kingdom